mci 9038 has been researched along with 2019 Novel Coronavirus Disease in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 17 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chunara, Z; Guy, S; Hopkins, B; Kitchen, S; Stephenson-Brown, A; van Veen, JJ | 1 |
| Lutchman, C; Margolin, E; Qian, J | 1 |
| González-Rodríguez, M; Lázaro-García, A; Llamas-Sillero, P; Martínez-Alfonzo, I; Tomás-Mallebrera, M; Velasco-Rodríguez, D; Vidal-Laso, R | 1 |
| Anderson, M; Chuck, C; Feler, J; Jayaraman, MV; McTaggart, R; Moldovan, K; Poggi, J; Sweeney, J; Torabi, R | 1 |
| Asmis, LM; Bachler, M; Fries, D; Koscielny, J; Lang, T; Nowak, H; Paulus, P; Schewe, JC; von Heymann, C | 1 |
| Alexander, GC; Mosley, SA; Ng, TMH; Qato, DM; Shooshtari, A; Wong, PJ | 1 |
| Kabrine, M; Mushtaq, M; Selmi, A; Tachoua, W; Ul-Haq, Z | 1 |
| Arachchillage, DJ; Hall, D; Laffan, M; Passariello, M; Patel, BV; Remmington, C; Rosenberg, A; Xu, T | 1 |
| Akiyama, T; Gohma, I; Kohata, H; Kohno, M; Kumasawa, J; Nagata, T; Nishida, K; Ogawa, Y | 1 |
| Daniels, LM; Sagardia, LM | 1 |
| Enright, H; Fahy, A; McGlynn, F; McGrath, J; McHugh, J; Ryan, B; Varghese, C | 1 |
| Al-Horani, RA; Aliter, KF | 1 |
| Gandotra, P; Garra, G; Gruberg, L; Selim, S; Supariwala, A | 1 |
| Barbar, T; Bhasin, A; Gerardine, S; Lamba, P; Leuprecht, L; Liu, F; Muthukumar, T; Neupane, SP; Salinas, T; Shankaranarayanan, D; Shimonov, D; Varma, E | 1 |
| Kawashima, M; Michiwaki, Y; Samura, K; Suehiro, E; Tabei, Y; Tanaka, T; Wakamiya, T | 1 |
| Arnold, F; Biever, PM; Kalbhenn, J; Neumann-Haefelin, E; Rieg, S; Tanriver, Y; Walz, G; Westermann, L | 1 |
| Brodmann, M; Gary, T; Guetl, K; Raggam, RB; Schmid, J; Wölfler, A | 1 |
2 review(s) available for mci 9038 and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Thromboprophylaxis with argatroban in critically ill patients with sepsis: a review.
Topics: Anticoagulants; Arginine; COVID-19; Critical Illness; Heparin; Heparin, Low-Molecular-Weight; Humans; Pipecolic Acids; Sepsis; Sulfonamides; Thrombocytopenia; Thrombosis; Venous Thromboembolism | 2022 |
Thrombin Inhibition by Argatroban: Potential Therapeutic Benefits in COVID-19.
Topics: Antithrombins; Arginine; Blood Coagulation; COVID-19; COVID-19 Drug Treatment; Drug Development; Humans; Inflammation; Pipecolic Acids; SARS-CoV-2; Sulfonamides | 2021 |
15 other study(ies) available for mci 9038 and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Laboratory methods for monitoring argatroban in heparin-induced thrombocytopenia.
Topics: Anticoagulants; Arginine; COVID-19; Drug Monitoring; Heparin; Humans; Partial Thromboplastin Time; Pipecolic Acids; Sulfonamides; Thrombocytopenia | 2022 |
Papilledema due to Vaccine-Induced Thrombocytopenia.
Topics: Antithrombins; Arginine; ChAdOx1 nCoV-19; COVID-19; Female; Glucocorticoids; Humans; Hydrocortisone; Immunoglobulins, Intravenous; Middle Aged; Ophthalmoscopy; Papilledema; Pipecolic Acids; Purpura, Thrombocytopenic, Idiopathic; SARS-CoV-2; Sinus Thrombosis, Intracranial; Sulfonamides; Vaccination | 2022 |
A journey through anticoagulant therapies in the treatment of left ventricular thrombus in post-COVID-19 heparin-induced thrombocytopenia: a case report.
Topics: Acenocoumarol; Anticoagulants; Arginine; COVID-19; COVID-19 Drug Treatment; Heparin; Hirudins; Humans; Male; Middle Aged; Peptide Fragments; Percutaneous Coronary Intervention; Pipecolic Acids; Recombinant Proteins; SARS-CoV-2; Sulfonamides; Thrombocytopenia; Thrombosis | 2022 |
Dual antiplatelet use in the management of COVID-19 associated acute ischemic stroke reocclusion.
Topics: Aspirin; Brain Ischemia; COVID-19; Humans; Ischemic Stroke; Middle Aged; Retrospective Studies; SARS-CoV-2; Stroke; Thrombectomy; Ticagrelor; Treatment Outcome | 2023 |
Changes in anticoagulant and antiplatelet drug supply at US hospitals before and during the COVID-19 pandemic (2018-2021).
Topics: Anticoagulants; COVID-19; Eptifibatide; Heparin; Hospitals; Humans; Pandemics; Platelet Aggregation Inhibitors | 2023 |
Highlights in TMPRSS2 inhibition mechanism with guanidine derivatives approved drugs for COVID-19 treatment.
Topics: Antihypertensive Agents; COVID-19; COVID-19 Drug Treatment; Famotidine; Guanidines; Humans; Ligands; Molecular Docking Simulation; Molecular Dynamics Simulation; Protease Inhibitors; SARS-CoV-2; Serine Endopeptidases | 2023 |
Anticoagulation with argatroban in patients with acute antithrombin deficiency in severe COVID-19.
Topics: Acute Disease; Adult; Anticoagulants; Antithrombins; Arginine; Betacoronavirus; Cohort Studies; Coronavirus Infections; COVID-19; Female; Humans; Incidence; Male; Middle Aged; Pandemics; Pipecolic Acids; Pneumonia, Viral; SARS-CoV-2; Severity of Illness Index; Sulfonamides; Thrombophilia | 2020 |
Argatroban therapy for heparin-induced thrombocytopenia in a patient with coronavirus disease 2019.
Topics: Adult; Anticoagulants; Antithrombins; Arginine; Betacoronavirus; Blood Coagulation; Coronavirus Infections; COVID-19; Heparin; Host-Pathogen Interactions; Humans; Male; Pandemics; Pipecolic Acids; Pneumonia, Viral; Pulmonary Embolism; SARS-CoV-2; Sulfonamides; Thrombocytopenia; Treatment Outcome | 2020 |
Thrombolysis and use of argatroban for the treatment of massive pulmonary embolism following anticoagulation failure in a patient with COVID-19.
Topics: Adult; Anticoagulants; Arginine; Coronavirus Infections; COVID-19; Fibrinolytic Agents; Heart Arrest; Heparin, Low-Molecular-Weight; Humans; Male; Pandemics; Pipecolic Acids; Pneumonia, Viral; Pulmonary Embolism; Sulfonamides; Thrombolytic Therapy; Treatment Failure; Treatment Outcome | 2020 |
Argatroban for therapeutic anticoagulation for heparin resistance associated with Covid-19 infection.
Topics: Adult; Anticoagulants; Arginine; Catheter Obstruction; COVID-19; Drug Resistance; Drug Substitution; Fibrin Fibrinogen Degradation Products; Heparin; Humans; Male; Middle Aged; Pipecolic Acids; Pulmonary Embolism; Respiration, Artificial; SARS-CoV-2; Sulfonamides; Thrombosis; Tomography, X-Ray Computed; Treatment Outcome | 2021 |
Aortic Arch Thrombus and Pulmonary Embolism in a COVID-19 Patient.
Topics: Anticoagulants; Antithrombins; Aorta, Thoracic; Arginine; Biomarkers; COVID-19; Female; Heparin; Humans; Middle Aged; Pipecolic Acids; Pneumonia, Viral; Pulmonary Embolism; SARS-CoV-2; Sulfonamides; Thrombosis | 2021 |
Anticoagulation Strategies and Filter Life in COVID-19 Patients Receiving Continuous Renal Replacement Therapy: A Single-Center Experience.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Arginine; Citric Acid; Continuous Renal Replacement Therapy; COVID-19; Disposable Equipment; Equipment Failure; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Pipecolic Acids; SARS-CoV-2; Sulfonamides; Time Factors | 2020 |
Emergent Carotid Artery Stenting Following Intravenous Alteplase Infusion After Rapid Negative Diagnosis for COVID-19 by Loop-Mediated Isothermal Amplification Assay.
Topics: Aged; Arginine; Carotid Stenosis; Combined Modality Therapy; COVID-19; Fibrinolytic Agents; Hemiplegia; Humans; Ischemic Stroke; Magnetic Resonance Imaging; Male; Molecular Diagnostic Techniques; Nucleic Acid Amplification Techniques; Pipecolic Acids; Platelet Aggregation Inhibitors; Stents; Sulfonamides; Tissue Plasminogen Activator; Tomography, X-Ray Computed; Treatment Outcome | 2021 |
Comparison of different anticoagulation strategies for renal replacement therapy in critically ill patients with COVID-19: a cohort study.
Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Arginine; Betacoronavirus; Blood Coagulation; Citric Acid; Comorbidity; Coronavirus Infections; COVID-19; Critical Care; Critical Illness; Equipment Failure; Female; Germany; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Pandemics; Pipecolic Acids; Pneumonia, Viral; Renal Replacement Therapy; Retrospective Studies; SARS-CoV-2; Sulfonamides; Tertiary Care Centers | 2020 |
SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia treated with immunoglobulin and argatroban.
Topics: Antithrombins; Arginine; COVID-19; COVID-19 Vaccines; Female; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Middle Aged; Pipecolic Acids; Purpura, Thrombocytopenic; SARS-CoV-2; Sulfonamides | 2021 |